Real-time AI system to measure colorectal polyp size during colonoscopy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective study will use EndoAIM, an artificial intelligence tool that automatically estimates polyp diameter in real time during colonoscopy. Measurements from EndoAIM will be recorded during routine colonoscopies at Prince of Wales Hospital and compared with endoscopists' visual estimates and available reference measurements (for example calibrated instruments or resected specimen measurements) to characterize accuracy, particularly around the 10 mm threshold. The study enrolls adults aged 18 and older undergoing screening, surveillance, or symptom investigation who can provide informed consent and excludes those with contraindications to colonoscopy or polyp resection and those with severe comorbidities (ASA grade 4+). Preclinical data for EndoAIM are promising and the trial aims to establish its real-time performance and potential to reduce size misclassification observed with visual estimation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Subjects are eligible if:

1. They have received colonoscopy for screening, surveillance or symptom investigation;
2. Aged 18 years older or above;
3. Written informed consent obtained.

Exclusion Criteria:

Subjects are excluded if they have:

1. Contraindication to colonoscopy (e.g. intestinal obstruction or perforation)
2. Contraindication or conditions precluding polyp resection (e.g. active gastrointestinal bleeding, uninterrupted anticoagulation or dual antiplatelets)
3. Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above)

Where it's running

• Prince of Wales Hospital
  Shatin, Hong Kong Recruiting

Study contacts

• Principal investigator: Louis HS Lau, FRCP — Chinese University of Hong Kong
• Study coordinator: Louis HS Lau, FRCP
• Email: louishslau@cuhk.edu.hk
• Phone: 26370428

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-assisted whole-course management for safe medicine use in advanced solid tumors

  A real-world study compares a smartphone-based digital management system with usual care to see if it reduces drug-related problems and healthcare needs for adults with advanced solid tumors receiving cancer therapy.

  Recruiting at 2 sites Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality and 1 other locations · NCT07917351

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• HDM2017 combination therapy in advanced colorectal cancer

  A small and mid-size study tests HDM2017 with standard chemotherapy and targeted drugs to see if it’s safe and may help people with unresectable or metastatic colorectal cancer.

  Recruiting Phase 1/2 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07805551

• AI-assisted and traditional workflows for admission diagnosis and management planning

  This trial tests whether an AI-agent workflow helps doctors make better admission diagnoses and care plans on simulated cases, compared with plain AI-assisted and traditional workflows.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07760051

• Retlirafusp alfa with bevacizumab and chemotherapy (with or without short radiotherapy) for colorectal cancer liver metastases

  This study tests whether adding retlirafusp alfa to bevacizumab and chemotherapy, with or without short-course radiotherapy, can help patients with advanced colorectal cancer that has spread to the liver.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07728019

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.